Investors

Press Releases

Date Title View
Toggle Summary Tetraphase Pharmaceuticals Completes Enrollment of IGNITE4 Phase 3 Clinical Trial of Eravacycline in Complicated Intra-abdominal Infections
 Accelerated Timelines for Both Top-line IGNITE4 Eravacycline Data and MAA filing in Europe ; Both Now Expected in 3Q 2017   IGNITE4 Results to Support U.S. NDA Filing for IV Eravacycline in cIAI  WATERTOWN, Mass. , April 03, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc.
View HTML
Toggle Summary Tetraphase Pharmaceuticals' TP-6076 Selected by CARB-X to Receive $4 Million in Research Funding
Funding initiative focused on urgent public health crisis of antibiotic resistance
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
WATERTOWN, Mass. , March 27, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and Highlights Key 2017 Milestones
  -Event-Driven 2017 Includes MAA Filing for IV Eravacycline in Europe and Top-Line Data Readout from IGNITE4 in cIAI - - Company to Host Conference Call Today, March 8, 2017 at 4:30 p.m. ET - WATERTOWN, Mass. , March 08, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc.
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at the 29th Annual ROTH Conference
WATERTOWN, Mass. , March 06, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Host Conference Call on March 8 to Discuss Fourth Quarter and Full Year 2016 Financial Results and Provide Corporate Update
WATERTOWN, Mass. , March 03, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will report fourth
View HTML
Toggle Summary Tetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI
WATERTOWN, Mass. , Jan. 17, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced dosing of the first patient in IGNITE3, the Company's phase 3 clinical trial evaluating the efficacy and safety of once-daily intravenous (IV) eravacycline compared to ertapenem in
View HTML
Toggle Summary Tetraphase Pharmaceuticals Provides Regulatory and Clinical Update for Eravacycline
- Company to Submit MAA for Eravacycline for the Treatment of Complicated Intra-Abdominal Infections to the EMA in Second Half of 2017 - - Phase 3 IGNITE3 Study in Complicated Urinary Tract Infections to Commence in First Quarter of 2017 - WATERTOWN, Mass. , Dec.
View HTML
Toggle Summary Tetraphase Publishes Phase 3 IGNITE1 Eravacycline Data in JAMA Surgery
WATERTOWN, Mass. , Nov. 17, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced the publication of results from IGNITE1, the
View HTML
Toggle Summary Tetraphase Pharmaceuticals to Present at Stifel 2016 Healthcare Conference
WATERTOWN, Mass. , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that company management will give a corporate
View HTML